Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | RXRA | P19793 | 10/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.46 |
| ▸ | RXRB | P28702 | 5/20 | 0.46 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.46 |
| ▸ | RARB | P10826 | 6/20 | 0.43 |
| ▸ | RARG | P13631 | 6/20 | 0.43 |
| ▸ | RARA | P10276 | 4/20 | 0.42 |
| ▸ | RXRG | P48443 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734636 | 0.92 | CYP3A4 (0.51) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL6729166 | 0.87 | RXRA (0.59) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL6733785 | 0.85 | RXRA (0.46) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL6733888 | 0.84 | CYP3A4 (0.45) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL6730498 | 0.83 | CYP3A4 (0.47) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL7769613 | 0.83 | RXRA (0.40) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL6733050 | 0.81 | CYP3A4 (0.45) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL8101333 | 0.80 | RARB (0.47) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL7771786 | 0.80 | RXRA (0.44) | CYP3A4RXRACYP26A1RXRBCYP26B1 | |
| SCHEMBL1018779 | 0.80 | RARB (0.58) | CYP3A4CYP26A1RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | DIAZ PHILIPPE (FR) | 2004-08-19 | — | — | US | claimed |
| EP-0823903-B1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CT INTERNAT DE RECH S (FR) | 2001-07-18 | — | — | EP | claimed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | claimed |
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | DIAZ PHILIPPE (FR) | 2004-08-19 | — | — | US | disclosed |
| US-6030952-A | AS HUMAN AND VETERINARY MEDICINE, PARTICULARLY IN THE TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGIC CONDITIONS, AND IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (FR) | 2000-02-29 | — | — | US | disclosed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | TYR, MITF, CYP1B1 | CYP3A4 147/4885RXRA 407/4885CYP26A1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.